03:09 PM EST, 12/19/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday it signed a three-year agreement with the US government aiming to reduce drug costs for Americans.

The agreement includes discounts on certain existing medicines within the Medicaid program and a direct-to-patient program offering discounts to Gilead's Hepatitis C treatment Epclusa, the company said.

Gilead said it also entered into an agreement with the Department of Commerce to be exempt from Section 232 pharmaceutical tariffs for three years, provided Gilead further invests in manufacturing in the country.

Based on the agreement terms, the company said it expects the financial impact to be "manageable" in 2026 and beyond.

Additional terms of the agreement with the government remain confidential, Gilead said.

Price: 125.35, Change: +3.88, Percent Change: +3.19